Lactose-free Infant Formula Does Not Change Outcomes of Neonatal Abstinence Syndrome (NAS): a Randomized Clinical Trial

Overview

Journal J Perinatol

Specialty Gynecology & Obstetrics

Date 2020 Sep 2

PMID 32868858

Citations 6

Authors

Rajesh Pandey

Neelakanta Kanike

Mugahid Ibrahim

Namita Swarup

Dennis M Super

Sharon Groh-Wargo

Deepak Kumar

Affiliations

Soon will be listed here.

Abstract

Objective: To determine if lactose-free formula, compared to lactose-containing formula, decreases the cumulative morphine dose required to treat neonatal abstinence syndrome (NAS).

Study Design: In a double-blind clinical trial, we randomized 74 infants (36-42 weeks gestation) at risk for developing NAS due to in-utero exposure to opioids to receive either lactose-free (Similac Sensitive®) or lactose-containing (Similac Advance®) infant formula. The primary outcome measure was the cumulative dose of morphine used for the treatment of NAS during the first 14 days of life.

Results: Data on 69 (4 withdrew consent and 1 ineligible)/74 randomized infants were analyzed. Patient characteristics between the infant groups fed lactose-free (n = 34) vs. lactose-containing (n = 35) infant formula were similar except more common maternal heroin abuse in the latter group (p = 0.013). Cumulative morphine dose (20.7 ± 19.8 vs. 23 ± 23.5 mg, p = 0.61) between the two groups were similar.

Conclusion: Lactose-free vs. lactose-containing infant formula did not change the outcomes of infants with NAS.

Citing Articles

Eligible Infants Included in Neonatal Clinical Trials and Reasons for Noninclusion: A Systematic Review.

Shaikh H, Lyle A, Oslin E, Gray M, Weiss E JAMA Netw Open. 2024; 7(10):e2441372.

PMID: 39453652 PMC: 11581680. DOI: 10.1001/jamanetworkopen.2024.41372.

Advances in the Care of Infants With Prenatal Opioid Exposure and Neonatal Opioid Withdrawal Syndrome.

Mascarenhas M, Wachman E, Chandra I, Xue R, Sarathy L, Schiff D Pediatrics. 2024; 153(2).

PMID: 38178779 PMC: 10827648. DOI: 10.1542/peds.2023-062871.

Race and Ethnicity of Infants Enrolled in Neonatal Clinical Trials: A Systematic Review.

Lyle A, Shaikh H, Oslin E, Gray M, Weiss E JAMA Netw Open. 2023; 6(12):e2348882.

PMID: 38127349 PMC: 10739112. DOI: 10.1001/jamanetworkopen.2023.48882.

Human milk fortification and use of infant formulas to support growth in the neonatal intensive care unit.

Moreira D, Gregory S, Younge N Nutr Clin Pract. 2023; 38 Suppl 2:S56-S65.

PMID: 37721458 PMC: 10662944. DOI: 10.1002/ncp.11038.

The immediate and long-term effects of prenatal opioid exposure.

Yen E, Davis J Front Pediatr. 2022; 10:1039055.

PMID: 36419918 PMC: 9676971. DOI: 10.3389/fped.2022.1039055.

References

Patrick S, Schumacher R, Benneyworth B, Krans E, McAllister J, Davis M . Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA. 2012; 307(18):1934-40. DOI: 10.1001/jama.2012.3951. View

Pansino F, Meara Jr J, Peppler J . Recurrent keratocysts in basal cell nevi syndrome. J Mich State Dent Assoc. 1974; 56(1):13-5. View

Ko J, Patrick S, Tong V, Patel R, Lind J, Barfield W . Incidence of Neonatal Abstinence Syndrome - 28 States, 1999-2013. MMWR Morb Mortal Wkly Rep. 2016; 65(31):799-802. DOI: 10.15585/mmwr.mm6531a2. View

Tolia V, Patrick S, Bennett M, Murthy K, Sousa J, Smith P . Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med. 2015; 372(22):2118-26. DOI: 10.1056/NEJMsa1500439. View

Nygaard E, Moe V, Slinning K, Walhovd K . Longitudinal cognitive development of children born to mothers with opioid and polysubstance use. Pediatr Res. 2015; 78(3):330-5. PMC: 4539602. DOI: 10.1038/pr.2015.95. View

Hudak M, Tan R . Neonatal drug withdrawal. Pediatrics. 2012; 129(2):e540-60. DOI: 10.1542/peds.2011-3212. View

Bogen D, Hanusa B, Baker R, Medoff-Cooper B, Cohlan B . Randomized Clinical Trial of Standard- Versus High-Calorie Formula for Methadone-Exposed Infants: A Feasibility Study. Hosp Pediatr. 2017; 8(1):7-14. PMC: 5744267. DOI: 10.1542/hpeds.2017-0114. View

Bogen D, Whalen B, Kair L, Vining M, King B . Wide Variation Found in Care of Opioid-Exposed Newborns. Acad Pediatr. 2016; 17(4):374-380. PMC: 5420467. DOI: 10.1016/j.acap.2016.10.003. View

Wilson-Costello D, Walsh M, Langer J, Guillet R, Laptook A, Stoll B . Impact of postnatal corticosteroid use on neurodevelopment at 18 to 22 months' adjusted age: effects of dose, timing, and risk of bronchopulmonary dysplasia in extremely low birth weight infants. Pediatrics. 2009; 123(3):e430-7. PMC: 2846831. DOI: 10.1542/peds.2008-1928. View

10.

Ballard O, Morrow A . Human milk composition: nutrients and bioactive factors. Pediatr Clin North Am. 2012; 60(1):49-74. PMC: 3586783. DOI: 10.1016/j.pcl.2012.10.002. View

11.

Abrams S, Griffin I, Davila P . Calcium and zinc absorption from lactose-containing and lactose-free infant formulas. Am J Clin Nutr. 2002; 76(2):442-6. DOI: 10.1093/ajcn/76.2.442. View

12.

Jansson L . ABM clinical protocol #21: Guidelines for breastfeeding and the drug-dependent woman. Breastfeed Med. 2009; 4(4):225-8. PMC: 2989871. DOI: 10.1089/bfm.2009.9987. View

13.

Hicks J, Morse E, Wyant D . Barriers and Facilitators of Breastfeeding Reported by Postpartum Women in Methadone Maintenance Therapy. Breastfeed Med. 2018; 13(4):259-265. DOI: 10.1089/bfm.2017.0130. View

14.

Isemann B, Meinzen-Derr J, Akinbi H . Maternal and neonatal factors impacting response to methadone therapy in infants treated for neonatal abstinence syndrome. J Perinatol. 2010; 31(1):25-9. DOI: 10.1038/jp.2010.66. View

15.

Begg E, Malpas T, Hackett L, Ilett K . Distribution of R- and S-methadone into human milk during multiple, medium to high oral dosing. Br J Clin Pharmacol. 2001; 52(6):681-5. PMC: 2014565. DOI: 10.1046/j.0306-5251.2001.01506.x. View

16.

Gray L, Miller L, Philipp B, Blass E . Breastfeeding is analgesic in healthy newborns. Pediatrics. 2002; 109(4):590-3. DOI: 10.1542/peds.109.4.590. View

17.

Mian P, Tibboel D, Wildschut E, van den Anker J, Allegaert K . Morphine treatment for neonatal abstinence syndrome: huge dosing variability underscores the need for a better clinical study design. Minerva Pediatr. 2017; 71(3):263-286. DOI: 10.23736/S0026-4946.17.04928-3. View

18.

Surran B, Visintainer P, Chamberlain S, Kopcza K, Shah B, Singh R . Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. J Perinatol. 2013; 33(12):954-9. DOI: 10.1038/jp.2013.95. View

19.

Gordon A, Lopatko O, Haslam R, Stacey H, Pearson V, Woods A . Ineffective morphine treatment regimen for the control of Neonatal Abstinence Syndrome in buprenorphine- and methadone-exposed infants. J Dev Orig Health Dis. 2014; 3(4):262-70. DOI: 10.1017/S2040174412000190. View

20.

Cleary B, Eogan M, OConnell M, Fahey T, Gallagher P, Clarke T . Methadone and perinatal outcomes: a prospective cohort study. Addiction. 2012; 107(8):1482-92. DOI: 10.1111/j.1360-0443.2012.03844.x. View